DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
GBT440 is an investigational drug.
There have been 18 clinical trials for GBT440. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2020.
The most common disease conditions in clinical trials are Anemia, Sickle Cell, Idiopathic Interstitial Pneumonias, and Fibrosis. The leading clinical trial sponsors are Global Blood Therapeutics, National Heart, Lung, and Blood Institute (NHLBI), and Mayo Clinic.
There are twelve US patents protecting this investigational drug and two hundred and sixteen international patents.
Recent Clinical Trials for GBT440
|Voxelotor Sickle Cell Exercise Study||Global Blood Therapeutics||Phase 4|
|Voxelotor Sickle Cell Exercise Study||Mednax Center for Research, Education, Quality and Safety||Phase 4|
|Voxelotor Sickle Cell Exercise Study||University of California, San Francisco||Phase 4|
Top disease conditions for GBT440
Top clinical trial sponsors for GBT440
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GBT440||Start Trial||Methods of treatment||Global Blood Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|GBT440||Start Trial||Compounds and uses thereof for the modulation of hemoglobin||Global Blood Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|GBT440||Start Trial||Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation||Global Blood Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|